Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis. (September 2014)

• Record Type: Journal Article
• Authors: Guerra, Federico; Matassini, Maria Vittoria; Scappini, Lorena; Urbinati, Alessia; Capucci, Alessandro
• Is Part Of: Expert review of cardiovascular therapy. Volume 12:Number 9(2014)
• Page Start: 1067
• Page End: 1075
• Publication Date: 2014-09
• Subjects: Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1586/14779072.2014.943662
• Languages: English
• ISSNs: 1477-9072

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Atrial fibrillation is the most common cardiac arrhythmia and is associated with increased mortality and morbidity. Conversion to sinus rhythm is usually appropriate in patients with acute, symptomatic atrial fibrillation in order to reduce symptoms and prevent complications. Electrical cardioversion is the most used and widespread technique, but requires deep sedation and a fasting state. Pharmacological alternatives are burdened by a delayed onset of action and potential proarrhythmic effects. Therefore, new therapeutic options are being sought. Among those, vernakalant, showed a good efficacy profile and a short onset of action, but with conflicting evidence regarding potential serious adverse events. This drug profile will summarize the pharmacology behind this new drug and review recent evidence in terms of safety and efficacy.</p> </abstract>